Sign in8 stories
The head and neck cancer trial combining PDS0101 with pembrolizumab reported 39.3-month median overall survival in checkpoint-inhibitor-naive patients, as the company pursues a partner for further development.
SEC filing
The company raised $11.3 million in an initial closing led by Nant Capital and redeemed a $6 million Yorkville note.
SEC filing (2)
The August 31, 2026 amendment reshapes repayment terms on a $6 million note, tying weekly ATM proceeds to note payments and extending a Nasdaq compliance cure period.
SEC filing
The board approved layoffs on August 6, 2026, to concentrate resources on PDS0301, and the company's COO departed the same week the cuts began.
SEC filing
The company's controller and CEO will take on interim finance officer roles effective September 12, 2026, following Boesgaard's departure.
SEC filing
The company will stop internally funding PDS0101 and seek a partner for it while making PDS0301 its lead program, alongside new colorectal cancer data.
SEC filing
The company said it will stop internal funding of the VERSATILE-003 Phase 3 trial and pursue partners for PDS0101 while advancing PDS0301 based on Phase 2 mCRC data.
SEC filing
The prospectus covers resale of up to 13,315,823 shares issuable to YA II PN, LTD. from a $6 million promissory note and a warrant tied to an April 2026 purchase agreement.
SEC filing